Figure 6
From: Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes
Limited PKC isoform degradation in cells following selected epoxytigliane treatment. (A) Western blot analysis of MM649 melanoma cells treated with 500 nM epoxytigliane analogues for the indicated times before harvesting. W—cells exposed to the epoxytiglianes for the indicated times before removal, washing and normal media for an additional 24 h prior to harvesting. (B,C) Western blot analysis of (B) SK-MEL-28 human melanoma or (C) B16-F0 murine melanoma cells treated with 500 nM TT (EBC-46) or PMA for the indicated times prior to harvesting. W—cells exposed to the epoxytiglianes for the indicated times before removal, washing and normal media for an additional 24 h prior to harvesting.
